Clovis Oncology Inc. (NASDAQ:CLVS) shares were up 1.7% on Friday . The stock traded as high as $16.70 and last traded at $16.49, with a volume of 442,470 shares. The stock had previously closed at $16.21.

Several research analysts have weighed in on CLVS shares. Vetr lowered shares of Clovis Oncology from a “strong-buy” rating to a “buy” rating and set a $17.66 price objective for the company. in a report on Wednesday, May 25th. Stifel Nicolaus reissued a “buy” rating and set a $30.00 price objective on shares of Clovis Oncology in a report on Thursday, June 30th. SunTrust Banks Inc. started coverage on shares of Clovis Oncology in a report on Friday, August 5th. They set a “buy” rating and a $25.00 price objective for the company. Zacks Investment Research upgraded shares of Clovis Oncology from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Thursday. Finally, Credit Suisse Group AG restated a “hold” rating on shares of Clovis Oncology in a research report on Tuesday, July 12th. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $28.98.

The firm’s 50 day moving average is $14.57 and its 200 day moving average is $16.30. The stock’s market cap is $649.51 million.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.13) by $0.06. During the same quarter last year, the firm earned ($2.10) earnings per share. Analysts predict that Clovis Oncology Inc. will post ($8.16) earnings per share for the current year.

A hedge fund recently bought a new stake in Clovis Oncology stock. Trexquant Investment LP bought a new position in Clovis Oncology Inc. (NASDAQ:CLVS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 90,561 shares of the biopharmaceutical company’s stock, valued at approximately $3,170,000. Trexquant Investment LP owned approximately 0.24% of Clovis Oncology as of its most recent SEC filing.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.